The influence of the severity of metabolic disorders on the diameter of the stones in the gallbladder: clinical and instrumental and laboratory data


DOI: https://dx.doi.org/10.18565/therapy.2019.3.55-59

Osadchuk M.A., Kireeva N.V., Vasilieva I.N., Mironova E.D.

Department of polyclinic therapy of medical faculty of I.M. Sechenov First Moscow State medical University of the Ministry of Healthcare of Russia (Sechenovskiy University)
Gallstone disease (ICD) occupies a leading position among gastroenterological diseases in terms of prevalence, complicated course, frequency of surgical interventions with a significant financial burden on the health care system. The combination of gallstones with metabolic disorders creates certain difficulties in the tactics of management of such patients.
The purpose of this study was to determine the relationship between the severity of metabolic disorders and the diameter of stones in the gallbladder.
Material and methods. The study involved 60 patients with gallstones with varying degrees of severity of metabolic disorders between the ages of 42 and 65 years. The first group included 30 patients with concrements in the gallbladder with a diameter of less than 10 mm. The second group consisted of 30 patients with a calculus diameter in the gallbladder from 10 to 15 mm. Group 3 (comparison) was represented by 30 patients with various manifestations of metabolic disorders between the ages of 41 and 63 years without calculi in the gallbladder.
Results. It is established that an increase in the diameter of stones in the gallbladder depends on the frequency and severity of metabolic disorders.
Conclusion. Metabolic disorders are independent predictors of gallstones, the severity of which affects the occurrence and diameter of stones in the gallbladder.
Keywords: gallbladder calculi, gallstone disease, metabolic disorders
Read entire article

Literature


  1. Rodriguez S., Gaunt T.R., Guo Y., Zheng J., Barnes M.R. et al. Lipids, obesity and gallbladder disease in women: insights from genetic studies using the cardiovascular gene-centric 50K SNP array. Eur. J. Hum. Genet. EJHG. 2016; 24(1): 106–12. https://doi.org/10.1038/ejhg.2015.63

  2. Prazeres F., Santiago L. Prevalence of multimorbidity in the adult population attending primary care in Portugal: a cross-sectional study. BMJ Open. 2015; 5(9): 1–10. https://doi.org/10.1136/bmjopen-2015-009287

  3. Everhart J.E., Ruhl C.E. Burden of Digestive Diseases in the United States. Part I: Overall and Upper Gastrointestinal Diseases. Gastroenterology. 2009; 136(2): 376–86. https://doi.org/10.1053/j.gastro.2008.12.015

  4. Stinton L.M., Shaffer E.A. Epidemiology of gallbladder disease: cholelithiasis and cancer. Gut Liver. 2012; 6(2): 172–87. https://doi.org/10.5009/gnl.2012.6.2.172

  5. Lammert F., Gurusamy K., Ko C.W., Miquel J.-F., Méndez-Sánchez N., Portincasa P., van Erpecum K.J., van Laarhoven C.J., Wang D.Q.-H. Gallstones. Nat. Rev. Dis. Primer. 2016; 2: 16024. https://doi.org/10.1038/nrdp.2016.24

  6. Ahmed F., Baloch Q., Memon Z.A., Ali I. An observational study on the association of nonalcoholic fatty liver disease and metabolic syndrome with gall stone disease requiring cholecystectomy. Ann. Med. Surg. 2017; 17: 7–13. https://doi.org/10.1016/j.amsu.2017.03.015

  7. Shabanzadeh D.M., Sorensen L.T., Jorgensen T. Determinants for gallstone formation - a new data cohort study and a systematic review with meta-analysis. Scand. J. Gastroenterol. 2016; 51(10): 1239–48. https://doi.org/10.1080/00365521.20.1182583

  8. Mendez-Sanchez N., Chavez-Tapia N.C., Motola-Kuba D., Sanchez-Lara K., Ponciano-Rodríguez G., Baptista H., Ramos M.H., Uribe M. Metabolic syndrome as a risk factor for gallstone disease. World J. Gastroenterol. 2005; 11(11), 1653–57. https://doi.org/10.3748/wjg.v11.i11.1653

  9. Nervi F., Miquel J.F., Alvarez M., Ferreccio C., Garcia-Zattera M.J., Gonzalez R., Perez-Ayuso R.M., Rigotti A., Villarroel L. Gallbladder disease is associated with insulin resistance in a high risk Hispanic population. J. Hepatol. 2006; 45(2): 299–305. https://doi.org/10.1016/j.jhep.2006.01.026

  10. Chen L.-Y., Qiao Q.-H., Zhang S.-C., Chen Y.-H., Chao G.-Q., Fang L.-Z. Metabolic syndrome and gallstone disease. World J. Gastroenterol. 2012; 18(31): 4215–20. https://doi.org/10.3748/wjg.v18.i31.4215

  11. Cojocaru C., Pandele G.I. Metabolic profile of patients with cholesterol gallstone disease. Rev. Med. Chir. Soc. Med. Nat. Iasi. 2010; 114: 677–82.

  12. Ata N., Kucukazman M., Yavuz B., Bulus H., Dal K., Ertugrul D.T., Yalcin A.A., Polat M., Varol N., Akin K.O., Karabag A., Nazligul Y. The metabolic syndrome is associated with complicated gallstone disease. Can. J. Gastroenterol. J. 2011; 25(5): 274–76. https://doi.org/10.1155/2011/356761

  13. Lammert F., Miquel J.-F. Gallstone disease: from genes to evidence-based therapy. J. Hepatol. 2008; 48(1): 124–35. https://doi.org/10.1016/j.jhep.2008.01.012

  14. Chang Y., Sung E., Ryu S., Park Y.-W., Jang Y.M., Park M. Insulin resistance is associated with gallstones even in non-obese, non-diabetic Korean men. J. Korean Med. Sci. 2008; 23(4): 644–50. https://doi.org/10.3346/jkms.2008.23.4.644

  15. Halldestam I., Enell E.L., Kullman E., Borch K. Development of symptoms and complications in individuals with asymptomatic gallstones. Br J Surg. 2004, 91(6): 734–38. https://doi.org/10.1002/bjs.4547

  16. Ata N., Kucukazman M., Yavuz B., Bulus H., Dal K., Ertugrul D.T., Yalcin A.A., Polat M., Varol N., Akin K.O., Karabag A., Nazligul Y. The metabolic syndrome is associated with complicated gallstone disease. Can J Gastroenterol. 2011, 25(5): 274–76. https://doi.org/10.1155/2011/356761


About the Autors

Mihail A. Osadchuk, MD, professor, the Head of the Department of polyclinic therapy of the faculty of medicine in I.M. Sechenov First Moscow State medical University of the Ministry of Healthcare of Russia (Sechenovskiy University). Address: 119435, Moscow, 2/4 Bolshaya Pirogovskaya str. Tel.: + 7 (916) 071-26-26. E-mail: policlinic_therapy@mail.ru. eLibrary SPIN: 3108-0478, ORCID:0000-0003-0485-6802
Natalia V. Kireeva, PhD, associate professor at the Department of polyclinic therapy of the faculty of medicine in I.M. Sechenov First Moscow State medical University of the Ministry of Healthcare of Russia (Sechenovskiy University). Address: 119435, Moscow, 2/4 Bolshaya Pirogovskaya str. Tel.: + 7 (916) 283-37-87. E-mail: kireeva_nat@inbox.ru. eLibrary SPIN: 6814-1680, ORCID:0000-0002-3467-886X
Inna N. Vasilieva, PhD, associate professor at the department of polyclinic therapy of the faculty of medicine in I.M. Sechenov First Moscow State medical University of the Ministry of Healthcare of Russia (Sechenovskiy University). Address: 119435, Moscow, 2/4 Bolshaya Pirogovskaya str. E-mail: inniva77@mail.ru
Ekaterina D. Mironova, medical resident at the Department of polyclinic therapy of the faculty of medicine in I.M. Sechenov First Moscow State medical University of the Ministry of Healthcare of the Russia (Sechenovskiy University). Address: 119435, Moscow, 2/4 Bolshaya Pirogovskaya str. E-mail: yek.mironova1995@gmail.com


Similar Articles

Back to Content

Бионика Медиа